Clinical trials
Metastatic Pancreatic Cancer clinical trials
Below are recruiting metastatic pancreatic cancer clinical trials, each written for real people, not researchers. We’re tracking 418 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06600906Recruiting
MRI test to predict treatment response in pancreatic cancer
This study is testing a new MRI technique that may help predict how well pancreatic cancer treatments will work. You would receive a special substance (called hyperpolarized pyruvate) during a standard MRI scan.
San Francisco, CaliforniaAges 18 years+ - NCT06587061RecruitingPhase 2
HRS-4642 plus AG before and after surgery for pancreatic cancer
This trial tests a combination of two medications (HRS-4642 and AG) given before and after surgery for pancreatic cancer that can be removed. The goal is to see if this treatment helps prevent the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06584227RecruitingPhase 2
Adebrelimab and Chidamide for advanced pancreatic cancer
This trial tests a combination of two drugs (Adebrelimab and Chidamide) in people with advanced pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Nanjing, JiangsuAges 18–75 - NCT06576115RecruitingPhase 2
Combination therapy with device for metastatic pancreatic cancer
This trial tests whether adding a non-invasive device that uses low-level radio waves to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with pancreatic cancer that has spread to other parts of the body.
Clarkston, MichiganAges 18 years+ - NCT06533332RecruitingPhase 1
Testing ERX-315 for advanced solid tumors
This trial tests a new drug called ERX-315 for people with advanced solid tumors (like breast, ovarian, pancreatic, endometrial, or liver cancer) that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works.
Ryde, New South WalesAges 18 years+ - NCT06547736RecruitingPhase 2
Precision treatment for advanced pancreatic cancer
This trial tests personalized therapies for people with advanced pancreatic cancer that has spread or cannot be removed. It aims to find the best treatment based on your tumor's unique features.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06500052RecruitingPhase 1
Study of BL-M17D1 for HER2-positive or low-expression digestive tract and other solid tumors
This trial tests a new drug called BL-M17D1 for people with advanced or metastatic HER2-positive or low-expression gastrointestinal cancer and other solid tumors. The goal is to see if it is safe and effective.
Guangzhou, GuangdongAges 18–75 - NCT06483555RecruitingPhase 1/Phase 2
Drug combo for basal-like pancreatic cancer
This trial tests a combination of three drugs (gemcitabine, erlotinib, and nab-paclitaxel) for people with a specific type of pancreatic cancer called 'basal-like' PDAC. It aims to see if this targeted approach works better than standard treatment.
Chapel Hill, North CarolinaAges 18 years+ - NCT06479239RecruitingPhase 1/Phase 2
Immune cell therapy for advanced pancreatic cancer
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
Charlottesville, VirginiaAges 18 years+ - NCT06445062RecruitingPhase 1/Phase 2
RAS-targeting drugs for gastrointestinal cancers
This trial tests new drugs that target a specific genetic change (RAS) in gastrointestinal cancers like pancreatic and colorectal cancer. The goal is to see if these drugs can shrink or slow down the cancer.
Chandler, ArizonaAges 18 years+ - NCT06440005RecruitingPhase 1
Testing AGX101 for advanced solid tumors
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06411691RecruitingPhase 1
Vaccine plus immunotherapy for KRAS-mutant cancers
This trial tests a cancer vaccine designed to target KRAS-mutated tumors, combined with two immunotherapy drugs, for people with advanced colorectal or pancreatic cancer. It may help the immune system recognize and attack cancer cells.
Baltimore, MarylandAges 18 years+ - NCT06361888RecruitingPhase 2/Phase 3
Testing a new drug combo for advanced pancreatic cancer
This trial tests a combination of four drugs (surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine) as a first treatment for people whose pancreatic cancer has spread to other parts of the body. The goal is to see if this combination helps shrink tumors and improve survival.
Hefei, AnhuiAges 18–75 - NCT06278454RecruitingPhase 1
Radioactive injection for advanced pancreatic cancer
This trial tests a new radioactive injection called NRT6008 for people with pancreatic cancer that cannot be surgically removed. It aims to see if the treatment can shrink the tumor and improve survival.
Zhengzhou, HenanAges 18–80 - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
Duarte, CaliforniaAges 18 years+ - NCT06030622RecruitingPhase 1/Phase 2
Treatment for advanced pancreatic cancer after standard therapy
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
Brooklyn, New YorkAges 18 years+ - NCT05929885RecruitingPhase 2
Genotype-guided chemo for metastatic pancreatic cancer
This trial tests a chemo plan that includes different drugs and adjusts the irinotecan dose based on a patient’s genetic test (UGT1A1). It’s designed for people with pancreatic cancer that has spread or cannot be removed with surgery.
SingaporeAges 21–99 - NCT05837767Recruiting
Radiation study for tumors that spread to soft tissue areas
This study looks at how a planned form of palliative radiation therapy treats certain solid cancers that have spread outside the brain to larger soft-tissue areas. It may help shrink tumors and relieve symptoms, but it also asks you to meet specific safety and treatment-timing rules.
Basking Ridge, New JerseyAges 18 years+ - NCT05686226RecruitingPhase 2
Trial tests immune cells targeting HPV-16 cancers
This Phase 2 trial tests an immune-cell treatment (E7 TCR T cells) designed to attack cancers caused by HPV type 16. It may help people whose HPV-16+ cancer has come back or not responded to standard treatment.
Bethesda, MarylandAges 18 years+ - NCT05657743Recruiting
Radiation seeds study for advanced pancreatic cancer safety
This trial tests a radiation treatment that places tiny radioactive seeds directly into the tumor to treat advanced pancreatic cancer. It mainly focuses on safety and whether the treatment can be delivered effectively, especially for people who may not be able to have more chemotherapy or surgery.
HolonAges 18 years+ - NCT03556228RecruitingPhase 1/Phase 2
Tested medicine for tumors with TrkA changes, alone or with pembrolizumab
This early-phase study tests VMD-928, a targeted cancer medicine, for cancers that have TrkA-related tumor changes. It may be given by itself or with pembrolizumab to see if it can shrink tumors when standard treatments have not worked.
Santa Rosa, CaliforniaAges 18–80 - NCT05518903RecruitingPhase 2
Scan test to see tumor-support cells in pancreatic cancer
This trial tests a special imaging scan (a PET/CT with a tracer called 68Ga-FAPI-46) to look at “cancer-support” cells in people with localized pancreatic ductal adenocarcinoma. It may help doctors better understand the tumor and how it responds before surgery after initial treatment.
Rochester, MinnesotaAges 18 years+ - NCT05428358Recruiting
MRI helps choose which pancreatic cancer patients can have surgery
This trial studies whether adding an MRI scan improves the selection of people with pancreatic cancer who may benefit from surgery. It focuses on patients without liver spread and with tumors that are borderline or likely removable.
AalborgAges 18–99 - NCT05372614RecruitingPhase 1
Testing trastuzumab deruxtecan and neratinib for HER2-positive cancers
This trial tests a combination of two targeted drugs, trastuzumab deruxtecan (Enhertu) and neratinib, for people with solid tumors that have a HER2 gene change. The goal is to see if the combination is safe and works well for cancers that have not responded to at least one prior treatment.
Duarte, CaliforniaAges 18 years+
Hear when a new Metastatic Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metastatic pancreatic cancer?
- Yes. Clin2 currently lists 418 recruiting metastatic pancreatic cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metastatic pancreatic cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metastatic pancreatic cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.